(preprint 8/12) (Peer Reviewed)
Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial
RCT with 36 colchicine and 36 control patients, showing reduced length of hospitalization and oxygen therapy with treatment.
Lopes et al., 8/12/2020, Double Blind Randomized Controlled Trial, Brazil, South America, peer-reviewed, 34 authors.
risk of death, 80.0% lower, RR 0.20, p = 0.49, treatment 0 of 36 (0.0%), control 2 of 36 (5.6%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of ICU admission, 50.0% lower, RR 0.50, p = 0.67, treatment 2 of 36 (5.6%), control 4 of 36 (11.1%).
oxygen time, 38.5% lower, relative time 0.62, treatment 36, control 36.
hospitalization time, 22.2% lower, relative time 0.78, treatment 36, control 361.
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.